RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment advances in small cell lung cancer (SCLC)

(2017) Saiama N. Waqar et al.   PHARMACOLOGY & THERAPEUTICS

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

(2017) Hongjuan Zhao et al.   Clinical Epigenetics

Small Cell Lung Cancer

(2017) Gregory P. Kalemkerian et al.   Journal of the National Comprehensive Cancer Network

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

(2016) Bryan Oronsky et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells

(2016) D Sharma Das et al.   LEUKEMIA

Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

(2015) M. C. Pietanza et al.   CLINICAL CANCER RESEARCH

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

(2015) Tony Reid et al.   LANCET ONCOLOGY

Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702

(2015) Akira Inoue et al.   LUNG CANCER

Nitric oxide synthase in innate and adaptive immunity: an update

(2015) Christian Bogdan   TRENDS IN IMMUNOLOGY

Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics

(2015) Benjamin Bonavida et al.   Redox Biology

Mechanisms of Hypoxia-Mediated Immune Escape in Cancer

(2014) I. B. Barsoum et al.   CANCER RESEARCH

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   JOURNAL OF CLINICAL ONCOLOGY

Small steps of improvement in small-cell lung cancer (SCLC) within two decades: A comprehensive analysis of 484 patients

(2014) M. Fiegl et al.   LUNG CANCER

Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis

(2013) Demetrios Simos et al.   Clinical Lung Cancer

Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer

(2011) R. A. Juergens et al.   Cancer Discovery

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results

(2009) Isao Oze et al.   PLoS One

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Nitric oxide, apoptosis and macrophage polarization during tumor progression

(2008) Andreas Weigert et al.   NITRIC OXIDE-BIOLOGY AND CHEMISTRY